Pfizer
$27.63Change from previous close: −1.76%Absolute change: −$0.50
At a glance
- Revenue growth
- −1.65%
- 2025 vs 2024
- Net income growth
- −3.24%
- 2025 vs 2024
- Net margin
- 12.4%
- 2024: 12.6%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 835 | 2,615 | 5,348 | 4,603 | 2,335 | 6,721 | 6,714 | -1,781 | 1,090 | 5,240 | 3,456 | -1,208 |
| Depreciation and amortization | 1,611 | 1,610 | 1,660 | 1,658 | 1,614 | 1,788 | 1,747 | 1,727 | 1,732 | 1,666 | 1,555 | 1,568 |
| Capital expenditure | -533 | -436 | -845 | -602 | -564 | -917 | -651 | -637 | -704 | -1,044 | -810 | -914 |
| Investing cash flow | 2,106 | 785 | -6,146 | -2,430 | 3,274 | -1,623 | -2,057 | 4,600 | 1,732 | -10,996 | 888 | -25,485 |
| Financing cash flow | -3,663 | -2,856 | 596 | -2,477 | -5,227 | -5,114 | -4,636 | -2,459 | -4,931 | 5,442 | -3,779 | 27,174 |
| Dividends paid | -2,451 | -2,445 | -2,445 | -2,444 | -2,437 | -2,380 | -2,380 | -2,380 | -2,372 | -2,315 | -2,314 | -2,315 |
| Debt issued | — | — | 5,991 | 0.0 | — | 732 | 2,161 | 4,570 | 1,444 | 7,672 | -22.0 | 30,630 |
| Debt repaid | -1,186 | -127 | -2,906 | 6.0 | -2,434 | -3,452 | -4,411 | -4,586 | -3,617 | 103 | -1,406 | -1,000 |
| Effect of exchange rates | -4.0 | 19.0 | 5.0 | 2.0 | -7.0 | -29.0 | 9.0 | -18.0 | -28.0 | -1.0 | -32.0 | -5.0 |
| Net change in cash | -726 | 563 | -197 | -300 | 374 | -45.0 | 29.0 | 343 | -2,137 | -315 | 535 | 475 |
| Free cash flow | 302 | 2,179 | 4,503 | 4,001 | 1,771 | 5,804 | 6,063 | -2,418 | 386 | 4,196 | 2,646 | -2,122 |
| Levered free cash flow | 2,849 | 418 | 7,060 | 1,706 | 1,472 | 7,435 | 3,352 | 1,817 | -801 | 11,171 | -4,512 | 1,896 |